Intuitive has snagged a clearance from the FDA for a surgical stapler system designed for its single-port robotic platform, ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

The letter, addressed to Senate Health, Education, Labor and Pensions Committee (HELP) chair Bill Cassidy, R-IL, is written and supported by 207 biotech innovators, including industry heavyweights ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake of new data showing the RNA therapy ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

On Friday, a federal judge permanently blocked the National Institutes of Health from implementing indirect cost caps on ...

The Trump administration’s effort to slash federal funding to universities has found its latest targets, with the government ...